Pasar al contenido principal

TRATRAMIENTO COMBINADO CON TERAPIA CELULAR Y ANTICOAGULANTES PARA EL TRATAMIENTO DE LA LESION PULMONAR AGUDA

PI18/00677

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2018
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARC TAULI
Centro realización CORPORACION SANITARIA PARC TAULI

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles

  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Laffey, John|||0000-0002-1246-9573
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Background: Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) have been proposed as an alternative to live-cell administration for Acute Respiratory Distress Syndrome (ARDS). MSC-EVs can be chiefly influenced by the environment to which the MSCs are exposed. Here, lipopolysaccharide (LPS) priming of MSCs was used as a strategy to boost the natural therapeutic potential of the EVs in acute lung injury (ALI). Methods: The regenerative and immunemodulatory effect of LPS-primed MSC-EVs (LPS-EVs) and non-primed MSC-EVs (C-EVs) were evaluated in vitro on alveolar epithelial cells and macrophage-like THP-1 cells. In vivo, ALI was induced in adult male rats by the intrapulmonary instillation of HCl and LPS. Rats (n = 8 to 22/group) were randomized to receive a single bolus (1 × 10 particles) of LPS-EVs, C-EVs, or saline. Lung injury severity was assessed at 72 h in lung tissue and bronchoalveolar lavage. Results: In vitro, LPS-EVs improved wound regeneration and attenuated the inflammatory response triggered by the P. aeruginosa infection, enhancing the M2 macrophage phenotype. In in vivo studies, LPS-EVs, but not C-EVs, significantly decreased the neutrophilic infiltration and myeloperoxidase (MPO) activity in lung tissue. Alveolar macrophages from LPS-EVs-treated animals exhibited a reduced expression of CXCL-1, a key neutrophil chemoattractant. However, both C-EVs and LPS-EVs reduced alveolar epithelial and endothelial permeability, mitigating lung damage. Conclusions: EVs from LPS-primed MSCs resulted in a better resolution of ALI, achieving a greater balance in neutrophil infiltration and activation, while avoiding the complete disruption of the alveolar barrier. This opens new avenues, paving the way for the clinical implementation of cell-based therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological inhibition of the CCL2-CCR2 axis fails to reduce inflammation in a rat model of acute lung injury

  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Tantinyà, Neus
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Guillamat-Prats, Raquel|||0000-0001-6960-0985
New therapeutic approaches are needed to regulate inflammation and control monocyte recruitment in acute respiratory distress syndrome (ARDS). Excessive monocyte influx into the alveolar space can exacerbate lung damage, worsening patient outcomes. Delaying or reducing monocyte recruitment into the alveoli space after the injury has been proposed as a strategy to balance the inflammatory response and mitigate lung damage. In the present study, we assessed the possible role of the CCL2-CCR2 axis as a therapy for controlling acute lung injury after the initial neutrophil-driven influx. We administered a CCL2-antibody (CCL2-Ab) or a CCR2-antagonist (CCR2-Ant) locally into the lung following lung injury induced by HCl/LPS instillation. Our results show that after 24 h, both treatments transiently reduced monocyte infiltration into the bronchoalveolar space. After 72 h, neither CCL2-Ab nor CCR2-Ant sustained a reduced monocyte infiltration or significantly alleviated alveolar or lung inflammation. CCR2-Ant prevented an increase of alveolar permeability, but neither of both treatments, CCL2-Ab nor CCR2-Ant, improved lung damage or function. Our findings indicate that blocking the CCL2-CCR2 axis to control monocyte trafficking at early stages of lung injury is insufficient to control inflammation or prevent disease progression. These results highlight the complexity of ARDS pathophysiology and suggest that alternative strategies may be required to effectively modulate monocyte-driven lung inflammation.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Priming Mesenchymal Stem Cells with Lipopolysaccharide Boosts the Immunomodulatory and Regenerative Activity of Secreted Extracellular Vesicles

  • Areny Balagueró, Aina
  • Camprubí Rimblas, Marta
  • Campaña-Duel, Elena
  • Solé Porta, Anna
  • Ceccato, Adrián
  • Roig Serra, Anna
  • Laffey, John G.
  • Closa, Daniel
  • Artigas, Antonio
Mesenchymal stem cells (MSCs)-derived extracellular vesicles (EVs) have been proposed as an alternative to live-cell administration for Acute Respiratory Distress Syndrome (ARDS). MSC-EVs can be chiefly influenced by the environment to which the MSCs are exposed. Here, lipopolysaccharide (LPS) priming of MSCs was used as a strategy to boost the natural therapeutic potential of the EVs in acute lung injury (ALI). Methods: The regenerative and immunemodulatory effect of LPS-primed MSC-EVs (LPS-EVs) and non-primed MSC-EVs (C-EVs) were evaluated in vitro on alveolar epithelial cells and macrophage-like THP-1 cells. In vivo, ALI was induced in adult male rats by the intrapulmonary instillation of HCl and LPS. Rats (n = 8 to 22/group) were randomized to receive a single bolus (1 × 108 particles) of LPS-EVs, C-EVs, or saline. Lung injury severity was assessed at 72 h in lung tissue and bronchoalveolar lavage. Results: In vitro, LPS-EVs improved wound regeneration and attenuated the inflammatory response triggered by the P. aeruginosa infection, enhancing the M2 macrophage phenotype. In in vivo studies, LPS-EVs, but not C-EVs, significantly decreased the neutrophilic infiltration and myeloperoxidase (MPO) activity in lung tissue. Alveolar macrophages from LPS-EVs-treated animals exhibited a reduced expression of CXCL-1, a key neutrophil chemoattractant. However, both C-EVs and LPS-EVs reduced alveolar epithelial and endothelial permeability, mitigating lung damage. Conclusions: EVs from LPS-primed MSCs resulted in a better resolution of ALI, achieving a greater balance in neutrophil infiltration and activation, while avoiding the complete disruption of the alveolar barrier. This opens new avenues, paving the way for the clinical implementation of cell-based therapies., This work was supported by the Fundación Ramón Areces under grant CIVP19S8207; the Ministerio de Economía y Competitividad-Instituto de Salud Carlos III (ISCIII) under grant PI18/00677, Co-funded by the European Regional Development Fund; “A way to make Europe”; the Institut d’Investigació I Innovació Parc Taulí (I3PT) under grants CIR2020/028 and CIR2021/027; the European Society of Intensive Medicine (ESICM) under the Levi-Montalcini Biomedical Sciences Award; the Centro de Investigación Biomedica en Red de Enfermedades Respiratorias (CIBERES); and the Generalitat de Catalunya (2021SGR00446). E.C.-D. and A.S.-P. acknowledge receiving financial support from the Ministerio de Ciencia, Innovación y Universidades (FPU22/00725 and FPU21/04142, respectively); and AC acknowledges receiving financial support from ISCIII (Sara Borrell 2021: CD21/00087). The funding sources had no role in the design and conduct of this study; the collection, management, analysis and interpretation of the data; the preparation, review or approval of the manuscript; or in the decision to submit the manuscript for publication., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Anticoagulant Treatment in Severe ARDS COVID-19 Patients

  • Ceccato, Adrian|||0000-0001-9454-062X
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Morales-Quinteros, Luis|||0000-0002-8937-9824
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Patients with COVID-19 may complicate their evolution with thromboembolic events. Incidence of thromboembolic complications are high and also, patients with the critically-ill disease showed evidence of microthrombi and microangiopathy in the lung probably due to endothelial damage by directly and indirectly injured endothelial and epithelial cells. Pulmonary embolism, deep venous thrombosis and arterial embolism were reported in patients with COVID-19, and several analytical abnormal coagulation parameters have been described as well. D-dimer, longer coagulation times and lower platelet counts have been associated with poor outcomes. The use of anticoagulation or high doses of prophylactic heparin is controversial. Despite the use of anticoagulation or high prophylactic dose of heparin have been associated with better outcomes in observational studies, only in patients with non-critically ill disease benefits for anticoagulation was observed. In critically-ill patient, anticoagulation was not associated with better outcomes. Other measures such as antiplatelet therapy, fibrinolytic therapy or nebulized anticoagulants are being studied in ongoing clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioengineered extracellular vesicles, future of precision medicine for sepsis

  • Areny-Balagueró, Aina|||0000-0001-9611-1781
  • Solé-Porta, Anna|||0000-0002-6129-4087
  • Camprubí-Rimblas, Marta|||0000-0002-4085-5324
  • Campaña-Duel, Elena|||0000-0002-0658-6255
  • Ceccato, Adrian|||0000-0001-9454-062X
  • Roig i Serra, Anna|||0000-0001-6464-7573
  • Closa Autet, Daniel|||0000-0003-3797-3095
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
Sepsis is a syndromic response to infection and is frequently a final common pathway to death from many infectious diseases worldwide. The complexity and high heterogeneity of sepsis hinder the possibility to treat all patients with the same protocol, requiring personalized management. The versatility of extracellular vesicles (EVs) and their contribution to sepsis progression bring along promises for one-to-one tailoring sepsis treatment and diagnosis. In this article, we critically review the endogenous role of EVs in sepsis progression and how current advancements have improved EVs-based therapies toward their translational future clinical application, with innovative strategies to enhance EVs effect. More complex approaches, including hybrid and fully synthetic nanocarriers that mimic EVs, are also discussed. Several pre-clinical and clinical studies are examined through the review to offer a general outlook of the current and future perspectives of EV-based sepsis diagnosis and treatment.